Gufic Biosciences Limited (NSE:GUFICBIO)
India
· Delayed Price · Currency is INR 370.65
-2.15 (-0.58%)
Jun 13, 2025, 3:29 PM IST
Gufic Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 8,198 | 8,067 | 6,906 | 7,792 | 4,877 | Upgrade
|
| Revenue Growth (YoY) | 1.63% | 16.80% | -11.36% | 59.76% | 28.74% | Upgrade
|
| Cost of Revenue | 3,747 | 3,986 | 3,393 | 4,207 | 2,565 | Upgrade
|
| Gross Profit | 4,451 | 4,080 | 3,513 | 3,585 | 2,312 | Upgrade
|
| Selling, General & Admin | 1,271 | 1,132 | 940.25 | 913.47 | 691.2 | Upgrade
|
| Other Operating Expenses | 1,834 | 1,466 | 1,197 | 1,191 | 781.26 | Upgrade
|
| Operating Expenses | 3,315 | 2,769 | 2,360 | 2,294 | 1,635 | Upgrade
|
| Operating Income | 1,136 | 1,312 | 1,153 | 1,291 | 676.53 | Upgrade
|
| Interest Expense | -231.12 | -145.64 | -66.36 | -40.06 | -117.66 | Upgrade
|
| Interest & Investment Income | - | 14.13 | 14.13 | 18.8 | 14.51 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.97 | -29.61 | 6.93 | 14.34 | Upgrade
|
| Other Non Operating Income (Expenses) | 36.27 | -5.28 | -4.56 | -8.97 | -10.77 | Upgrade
|
| EBT Excluding Unusual Items | 941.43 | 1,180 | 1,067 | 1,268 | 576.95 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -0.21 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -23 | 0.3 | 0.68 | 0.37 | Upgrade
|
| Pretax Income | 941.43 | 1,157 | 1,067 | 1,268 | 577.12 | Upgrade
|
| Income Tax Expense | 244.95 | 295.36 | 270.16 | 309.98 | 134.8 | Upgrade
|
| Earnings From Continuing Operations | 696.49 | 861.36 | 797.05 | 958.4 | 442.32 | Upgrade
|
| Minority Interest in Earnings | 0.01 | - | - | - | - | Upgrade
|
| Net Income | 696.5 | 861.36 | 797.05 | 958.4 | 442.32 | Upgrade
|
| Net Income to Common | 696.5 | 861.36 | 797.05 | 958.4 | 442.32 | Upgrade
|
| Net Income Growth | -19.14% | 8.07% | -16.84% | 116.68% | 94.96% | Upgrade
|
| Shares Outstanding (Basic) | 100 | 99 | 97 | 97 | 97 | Upgrade
|
| Shares Outstanding (Diluted) | 100 | 99 | 97 | 97 | 97 | Upgrade
|
| Shares Change (YoY) | 1.72% | 1.63% | - | - | 24.56% | Upgrade
|
| EPS (Basic) | 6.95 | 8.74 | 8.22 | 9.89 | 4.56 | Upgrade
|
| EPS (Diluted) | 6.95 | 8.74 | 8.22 | 9.89 | 4.56 | Upgrade
|
| EPS Growth | -20.48% | 6.33% | -16.85% | 116.80% | 56.43% | Upgrade
|
| Free Cash Flow | 470.43 | -1,202 | -2,142 | 187.86 | 748.52 | Upgrade
|
| Free Cash Flow Per Share | 4.69 | -12.20 | -22.09 | 1.94 | 7.72 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | Upgrade
|
| Dividend Growth | - | - | - | - | 100.00% | Upgrade
|
| Gross Margin | 54.29% | 50.58% | 50.87% | 46.01% | 47.40% | Upgrade
|
| Operating Margin | 13.86% | 16.26% | 16.70% | 16.57% | 13.87% | Upgrade
|
| Profit Margin | 8.50% | 10.68% | 11.54% | 12.30% | 9.07% | Upgrade
|
| Free Cash Flow Margin | 5.74% | -14.89% | -31.01% | 2.41% | 15.35% | Upgrade
|
| EBITDA | 1,347 | 1,408 | 1,307 | 1,430 | 803.85 | Upgrade
|
| EBITDA Margin | 16.43% | 17.45% | 18.92% | 18.36% | 16.48% | Upgrade
|
| D&A For EBITDA | 210.65 | 96.33 | 153.43 | 139.3 | 127.32 | Upgrade
|
| EBIT | 1,136 | 1,312 | 1,153 | 1,291 | 676.53 | Upgrade
|
| EBIT Margin | 13.86% | 16.26% | 16.70% | 16.57% | 13.87% | Upgrade
|
| Effective Tax Rate | 26.02% | 25.53% | 25.31% | 24.44% | 23.36% | Upgrade
|
| Revenue as Reported | 8,234 | 8,088 | 6,932 | 7,823 | 4,914 | Upgrade
|
| Advertising Expenses | - | 21.23 | 59.56 | 33.44 | 18.57 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.